Genotyping for Severe Drug Hypersensitivity

Part of the following topical collections:
  1. Topical Collection on Anaphylaxis and Drug Allergy


Over the past decade, there have been significant advances in our understanding of the immunopathogenesis and pharmacogenomics of severe immunologically-mediated adverse drug reactions. Such T-cell-mediated adverse drug reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug-induced liver disease (DILI) and other drug hypersensitivity syndromes have more recently been shown to be mediated through interactions with various class I and II HLA alleles. Key examples have included the associations of HLA-B*15:02 and carbamazepine induced SJS/TEN in Southeast Asian populations and HLA-B*57:01 and abacavir hypersensitivity. HLA-B*57:01 screening to prevent abacavir hypersensitivity exemplifies a successful translational roadmap from pharmacogenomic discovery through to widespread clinical implementation. Ultimately, our increased understanding of the interaction between drugs and the MHC could be used to inform drug design and drive pre-clinical toxicity programs to improve drug safety.


Genotyping Altered peptide repertoire DILI DRESS Human leukocyte antigen Drug hypersensitivity Major histocompatibility complex Pharmacogenetics Pharmacogenomics Stevens-Johnson syndrome Toxic epidermal necrolysis Translation SCAR 


Papers of particular interest, published recently, have been highlighted as: •Of importance; ••Of major importance

  1. 1.
    Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017–25.PubMedGoogle Scholar
  2. 2.
    Khan LM. Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay - a systematic review. Eur J Clin Pharmacol. 2013.Google Scholar
  3. 3.
    Suh DC et al. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 2000;34(12):1373–9.PubMedGoogle Scholar
  4. 4.
    Pirmohamed M et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9.PubMedGoogle Scholar
  5. 5.
    Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2012;13(11):1285–306.PubMedGoogle Scholar
  6. 6.
    Schnyder B et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest. 1997;100(1):136–41.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Zanni MP et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest. 1998;102(8):1591–8.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Zanni MP et al. Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific alphabeta + T cell clones. Int Immunol. 1998;10(4):507–15.PubMedGoogle Scholar
  9. 9.
    Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683–93.PubMedGoogle Scholar
  10. 10.
    Bharadwaj M et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol. 2012;52:401–31.PubMedGoogle Scholar
  11. 11.••
    Norcross MA et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS. 2012;26(11):F21–9. Using abacavir-treated HLA-B*57:01 B-cell lines, the authors demonstrated additional evidence that abacavir alters the quantity and quality of self-peptide loading into HLA-B*57:01.PubMedGoogle Scholar
  12. 12.••
    Wei CY et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol. 2012;129(6):1562–9 e5. This article demonstrates a direct interaction of HLA molecules with drugs and provides a potential mechanism for HLA-associated drug hypersensitivity reactions. Supportive of altered peptide repertoire model for carbamazepine.PubMedGoogle Scholar
  13. 13.••
    Illing PT et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012;486(7404):554–8. Study supporting the altered peptide repertoire model for abacavir hypersensitivity. Abacavir associates with HLA-B*57:01 non-covalently and alters the shape and chemistry of the antigen-binding cleft. This leads to an altered repertoire of endogenous peptides binding HLA-B*57:01. The crystal structure of abacavir-MHC-peptide was resolved using an endogenous peptide. Preliminary evidence to support the altered peptide repertoire model for was also presented.PubMedGoogle Scholar
  14. 14.••
    Ostrov DA et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A. 2012;109(25):9959–64. Provided structural, biochemical and functional evidence for non-covalent interaction between abacavir and HLA-B*57:01 and the altered repertoire model for abacavir. A synthetic peptide was derived that binds to HLA-B*57:01 only in the presence of abacavir. The crystal structure of abacavir-MHC-peptide was resolved using this peptide.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Cutrell AG et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38(12):2171–2.PubMedGoogle Scholar
  16. 16.
    Shapiro M, Ward KM, Stern JJ. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS Read. 2001;11(4):222–6.PubMedGoogle Scholar
  17. 17.
    Symonds W et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24(4):565–73.PubMedGoogle Scholar
  18. 18.
    Mallal S et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–32.PubMedGoogle Scholar
  19. 19.
    Hetherington S et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121–2.PubMedGoogle Scholar
  20. 20.
    Hughes AR et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5(2):203–11.PubMedGoogle Scholar
  21. 21.
    Saag M et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7):1111–8.PubMedGoogle Scholar
  22. 22.
    Mallal S et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568–79.PubMedGoogle Scholar
  23. 23.
    Schackman BR et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008;22(15):2025–33.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Rauch A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43(1):99–102.PubMedGoogle Scholar
  25. 25.
    Guo Y et al. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci. 2013;56(2):119–24.PubMedGoogle Scholar
  26. 26.
    Chessman D et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008;28(6):822–32.PubMedGoogle Scholar
  27. 27.••
    Adam J et al. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol. 2012;42(7):1706–16. Paper providing evidence that abacavir interacts with HLA-B*57:01 in a non-covalent and metabolism-independent fashion. Additionally, this study provided evidence that abacavir-reactive T-cell clones are dependent on the drug concentration, TCR avidity and level of HLA-B*57:01 molecules expressed on APCs.PubMedGoogle Scholar
  28. 28.
    Knowles SR, Dewhurst N, Shear N. Anticonvulsant hypersensitivity syndrome: an update. Expert Opin Drug Saf. 2012;11(5):767–78.PubMedGoogle Scholar
  29. 29.•
    McCormack M et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134–43. First GWAS for carbamazepine in Europeans that identified an association with HLA-A*31:01 and individuals of northern European ancestry with various phenotypes of carbamazepine-induced hypersensitivity reactions. Although this study suggested an association between HLA-A*31:01 and carbamazepine SJS/TEN in European populations, not all follow-up studies have supported this.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Chung WH et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.PubMedGoogle Scholar
  31. 31.
    Kulkantrakorn K et al. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract. 2012;12(3):202–8.PubMedGoogle Scholar
  32. 32.
    Mehta TY et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009;75(6):579–82.PubMedGoogle Scholar
  33. 33.
    Then SM et al. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol. 2011;29(3):290–3.PubMedGoogle Scholar
  34. 34.
    Man CB et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015–8.PubMedGoogle Scholar
  35. 35.
    Wang Q et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure. 2011;20(6):446–8.PubMedGoogle Scholar
  36. 36.
    Zhang Y et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol. 2011;67(9):885–7.PubMedGoogle Scholar
  37. 37.
    Chen P et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126–33.PubMedGoogle Scholar
  38. 38.•
    Ko TM et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 2011;128(6):1266–76. Important in vitro study that establishes the essential role of the TCR in the mechanism behind SJS/TEN and explains why some HLA-B*15:02 carriers are tolerant to carbamazepine.PubMedGoogle Scholar
  39. 39.
    Mizumoto K et al. Case of carbamazepine-induced hypersensitivity syndrome associated with human leukocyte antigen-A*3101. J Dermatol. 2012;39(9):791–2.PubMedGoogle Scholar
  40. 40.
    Niihara H et al. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012;39(7):594–601.PubMedGoogle Scholar
  41. 41.•
    Ozeki T et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034–41. GWAS that showed association with HLA-A*31:01 and carbamazepine-induced immunologically mediated adverse drug reactions in those of Japanese ancestry.PubMedGoogle Scholar
  42. 42.
    Yip VL et al. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther. 2012;92(6):757–65.PubMedGoogle Scholar
  43. 43.
    Amstutz U et al. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013;94(1):142–9.PubMedGoogle Scholar
  44. 44.
    Ramasamy SN et al. Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950-2012. Drug Saf. 2013.Google Scholar
  45. 45.
    Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966;64(2):229–58.PubMedGoogle Scholar
  46. 46.
    Lang Jr PG. Severe hypersensitivity reactions to allopurinol. South Med J. 1979;72(11):1361–8.PubMedGoogle Scholar
  47. 47.
    Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20(5):391–5.PubMedGoogle Scholar
  48. 48.
    Chan SH, Tan T. HLA and allopurinol drug eruption. Dermatologica. 1989;179(1):32–3.PubMedGoogle Scholar
  49. 49.
    Hung SI et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134–9.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Dainichi T et al. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology. 2007;215(1):86–8.PubMedGoogle Scholar
  51. 51.
    Kaniwa N et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9(11):1617–22.PubMedGoogle Scholar
  52. 52.
    Tassaneeyakul W et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19(9):704–9.PubMedGoogle Scholar
  53. 53.
    Jung JW et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant. 2011;26(11):3567–72.PubMedGoogle Scholar
  54. 54.
    Kang HR et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21(5):303–7.PubMedGoogle Scholar
  55. 55.
    Lonjou C et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18(2):99–107.PubMedGoogle Scholar
  56. 56.
    Genin E et al. Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J Rare Dis. 2011;6:52.PubMedCentralPubMedGoogle Scholar
  57. 57.
    Tohkin M et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 2013;13(1):60–9.PubMedGoogle Scholar
  58. 58.
    Somkrua R et al. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12:118.PubMedCentralPubMedGoogle Scholar
  59. 59.
    Pompeu YA et al. The structural basis of HLA-associated drug hypersensitivity syndromes. Immunol Rev. 2012;250(1):158–66.PubMedGoogle Scholar
  60. 60.
    Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20(6):1071–92.PubMedGoogle Scholar
  61. 61.
    Gangar M et al. Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. Ann Pharmacother. 2000;34(7–8):839–42.PubMedGoogle Scholar
  62. 62.
    Martin AM et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19(1):97–9.PubMedGoogle Scholar
  63. 63.••
    Yuan J et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS. 2011;25(10):1271–80. Genetic study investigating different clinical presentations of nevirapine hypersensitivity and reporting several new associations with specific HLA alleles.PubMedCentralPubMedGoogle Scholar
  64. 64.
    Vitezica ZG et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008;22(4):540–1.PubMedGoogle Scholar
  65. 65.••
    Phillips E et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013;62(2):e55–7. A class II allele DRB1*01:02 which is homologous to DRB1*01:01 is related to nevirapine-associated hepatitis in South African Black populations.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Littera R et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS. 2006;20(12):1621–6.PubMedGoogle Scholar
  67. 67.
    Gatanaga H et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS. 2007;21(2):264–5.PubMedGoogle Scholar
  68. 68.
    Gao S et al. HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients. AIDS Res Hum Retroviruses. 2012;28(6):540–3.PubMedGoogle Scholar
  69. 69.
    Chantarangsu S et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics. 2009;19(2):139–46.PubMedGoogle Scholar
  70. 70.
    Chantarangsu S et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin Infect Dis. 2011;53(4):341–8.PubMedGoogle Scholar
  71. 71.
    Likanonsakul S et al. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther. 2009;6:22.PubMedCentralPubMedGoogle Scholar
  72. 72.••
    Carr DF et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis. 2013;56(9):1330–9. First study to associate HLA-C*04:01 with nevirapine-associated Stevens-Johnson Syndrome/Toxic epidermal necrolysis in a Black African population.PubMedGoogle Scholar
  73. 73.
    Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44(1):116–26.PubMedGoogle Scholar
  74. 74.
    Hautekeete ML et al. HLA association of amoxicillin-clavulanate–induced hepatitis. Gastroenterology. 1999;117(5):1181–6.PubMedGoogle Scholar
  75. 75.
    O’Donohue J et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47(5):717–20.PubMedGoogle Scholar
  76. 76.
    Donaldson PT et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol. 2010;53(6):1049–53.PubMedGoogle Scholar
  77. 77.
    Lucena MI et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141(1):338–47.PubMedCentralPubMedGoogle Scholar
  78. 78.
    Lucena MI et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44(4):850–6.PubMedGoogle Scholar
  79. 79.
    Stephens C et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013;8(7):e68111.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Olsson R et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol. 1992;15(1–2):154–61.PubMedGoogle Scholar
  81. 81.
    Russmann S et al. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol. 2005;60(1):76–82.PubMedCentralPubMedGoogle Scholar
  82. 82.
    Daly AK et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816–9.PubMedGoogle Scholar
  83. 83.
    Phillips EJ, Mallal SA. HLA-B*5701 and flucloxacillin associated drug-induced liver disease. AIDS. 2013;27(3):491–2.PubMedGoogle Scholar
  84. 84.
    Ferrell Jr PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543–6.PubMedCentralPubMedGoogle Scholar
  85. 85.
    Phillips EJ et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19(9):979–81.PubMedGoogle Scholar
  86. 86.
    Shear NH et al. A review of drug patch testing and implications for HIV clinicians. AIDS. 2008;22(9):999–1007.PubMedGoogle Scholar
  87. 87.
    Phillips EJ et al. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS. 2002;16(16):2223–5.PubMedGoogle Scholar
  88. 88.
    Lee AY, Choi J, Chey WY. Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis. 2003;48(3):137–9.PubMedGoogle Scholar
  89. 89.
    Buyuktiryaki AB et al. Patch testing is an effective method for the diagnosis of carbamazepine-induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8-year-old girl. Australas J Dermatol. 2012;53(4):274–7.PubMedGoogle Scholar
  90. 90.
    Lin YT, et al. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol. 2012.Google Scholar
  91. 91.
    Phillips EJ, Mallal SA. HLA-B*1502 screening and toxic effects of carbamazepine. N Engl J Med. 2011;365(7):672. author reply 673.PubMedGoogle Scholar
  92. 92.
    Martin AM et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A. 2004;101(12):4180–5.PubMedCentralPubMedGoogle Scholar
  93. 93.
    Hammond E et al. External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antivir Ther. 2007;12(7):1027–32.PubMedGoogle Scholar
  94. 94.
    Martin AM et al. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics. 2006;16(5):353–7.PubMedGoogle Scholar
  95. 95.
    Melis R et al. Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity. Genet Test Mol Biomarkers. 2012;16(9):1111–4.PubMedGoogle Scholar
  96. 96.
    Zhang FR et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369(17):1620–8.PubMedGoogle Scholar
  97. 97.
    Pavlos R, Mallal S, Ostrov D, Pompeu Y, Phillips E. Fever, rash and systemic symptoms: understanding the role of virus and HLA in cutaneous drug allergy. J Allerg Clin Immunol In Practice. 2014;2(1):21–33.Google Scholar
  98. 98.
    Kim SH et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011;97(1–2):190–7.PubMedGoogle Scholar
  99. 99.
    Kaniwa N et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010;51(12):2461–5.PubMedGoogle Scholar
  100. 100.
    Ikeda H et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010;51(2):297–300.PubMedGoogle Scholar
  101. 101.
    Hung SI et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11(3):349–56.PubMedGoogle Scholar
  102. 102.
    Lin LC et al. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report. Kaohsiung J Med Sci. 2009;25(2):82–6.PubMedGoogle Scholar
  103. 103.
    Cheung YK et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54(7):1307–14.PubMedGoogle Scholar
  104. 104.
    Locharernkul C et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087–91.PubMedGoogle Scholar
  105. 105.
    Kaniwa N et al. Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics. 2013;14(15):1821–31.PubMedGoogle Scholar
  106. 106.
    Kim SH et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics. 2010;11(6):879–84.PubMedGoogle Scholar
  107. 107.
    Alfirevic A et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006;7(6):813–8.PubMedGoogle Scholar
  108. 108.
    Singer JB et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42(8):711–4.PubMedGoogle Scholar
  109. 109.
    Kindmark A et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8(3):186–95.PubMedGoogle Scholar
  110. 110.
    Spraggs CF et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29(6):667–73.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Vanderbilt University School of MedicineNashvilleUSA
  2. 2.Institute for Immunology and Infectious DiseasesMurdoch UniversityPerthAustralia

Personalised recommendations